Tacrolimus Ointment Interest (PROTOPIC ®) in the Maintenance Treatment of Severe Seborrheic Dermatitis

Severe Seborrheic Dermatitis Clinical Trial

— Disease  

Official title:

Phase 3 : Tacrolimus Ointment Interest (PROTOPIC ®) in the Maintenance Treatment of Severe Seborrheic Dermatitis on Adult Face

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02004860
• Other study ID #: 2011/104/HP
• Secondary ID: 2011-004186-32
• Status: Completed
• Phase: Phase 3
• Start date: January 2014
• Est. completion date: October 2017

Study information

• Verified date: May 2018
• Source: University Hospital, Rouen
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Seborrheic dermatitis is a chronic inflammatory dermatological disease, evolving by relapses, affecting mainly the face and scalp. It would be important to have a maintenance treatment for severe forms of seborrheic dermatitis witch is both effective and relatively well tolerated to reduce the frequency of relapses, prolong remissions obtained after attack treatment and reduce the use of topical steroids.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 120
• Est. completion date: October 2017
• Est. primary completion date: October 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• in Phase 1: Attack Treatment (open)

1. over the age of eighteen patient,

2. Seborrheic dermatitis Severe,

3. participation with an informed consent,

4. Women of childbearing age in effective contraception for the duration of the study or postmenopausal women.

• in Phase 2: Phase 2: "Randomization" (blind)

1. Patient achieved a complete or almost complete clinical remission after the initial treatment,

2. known immunodeficiency (HIV patient receiving chemotherapy) or immunosuppressive therapy or biotherapy,

3. patient taking regular systemic corticosteroids at a dose> 20 mg / day

4. erythematous lesions with topography other than the face and evocative scalp psoriasis (elbows, knees ...), by referring to the possibility that the facial lesions correspond to lesions sebopsoriasis,

5. woman pregnant, nursing or in childbearing potential without effective contraception,

6. man wishing to have a child during the study period,

7. Ultra Violet (UV) phototherapy or usual realization of UV sessions aesthetic purposes,

8. Seborrheic dermatitis symptomatic of an underlying disease known or revealing

9. history of cancer or lymphoma,

10. progressive cancer or lymphoma,

11. Seborrheic dermatitis exclusively affecting the scalp,

12. known allergy to one-component products study ,

13. malnourished patient or sick history of chronic pancreatitis by a suspect to deficiency dermatitis,

14. participation in a clinical trial on the Seborrheic dermatitis in the previous 90 days,

15. patient with lesions considered potentially malignant or pre-cancerous,

16. patient with abnormal skin barrier.

Exclusion Criteria:

• in Phase 1: Attack Treatment (open)

1) Patient had already been treated with Protopic ® for Seborrheic Dermatitis,

• Phase 2: "Randomization" (blind) 1) Patient with no complete or almost complete clinical remission after the initial treatment,

Related Conditions & MeSH terms

• Dermatitis
• Dermatitis, Seborrheic
• Severe Seborrheic Dermatitis

Intervention

Drug:
• Protopic (R)
Protopic® 0.1% ointment - 2 applications per week for 6 months
• Mycoster (R)
Mycoster 1% - 2 applications per week for 6 months

Locations

Country	Name	City	State
France	Rouen University Hospital	Rouen

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Rouen

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	duration of the maintenance of complete or almost complete clinical remission	The primary endpoint will be the duration of the maintenance of complete or almost complete clinical remission obtained after the initial treatment. This period is defined as the time from randomization to the first occurrence of relapse noted by the dermatologist.	18 months after inclusion (Visit (V) 4 last visit)
Secondary	Tolerance of 2 treatments	Tolerance of 2 treatments Mycoster (R) and Protocopic (R)	between 10 days and 18 months after inclusion (V3 (Day (D)10 to D180)), 30 days after inclusion (Visit D30), after 90 days after inclusion (D90) and after 120 days after inclusion (D120) and 180 days after inclusion (Visit V4)
Secondary	Number of Relapses	Number of Relapses requiring the resumption of topical corticosteroid treatment,	180 days after inclusion (Visit V4)
Secondary	Cumulative amount of corticosteroids applied	Cumulative amount of corticosteroids applied by the patients during the study period to control their outbreaks	between 10 days and 18 months after inclusion (V3 (D10 to D180)), 30 days after inclusion (Visit D30), after 90 days after inclusion (D90) and after 120 days after inclusion (D120) and 180 days after inclusion (Visit V4)
Secondary	quality of life of patients	quality of life of patients	Inclusion (visit D0) and Last visit 180 days after inclusion (Visit D180)